HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spinosa, D. J. Articles by McConnell, K. Search for Related Content PubMed PubMed Citation Articles by Spinosa, D. J. Articles by McConnell, K. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Safety of CO₂- and Gadodiamide-Enhanced Angiography for the Evaluation and Percutaneous Treatment of Renal Artery Stenosis in Patients with Chronic Renal Insufficiency

¹ Department of Radiology, University of Virginia Health System, Lee St., Box 170, Charlottesville, VA 22908.
² Department of Health Evaluation Sciences, University of Virginia Health System, Charlottesville, VA 22908.
³ Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908.
⁴ Department of Medicine, Martha Jefferson Hospital, Locust Ave., Charlottesville, VA 22901.

OBJECTIVE. The objective of our study was to evaluate the safety of CO₂ and gadodiamide angiography for diagnosing and percutaneously treating renal artery stenosis in patients with chronic renal insufficiency and presumed ischemic nephropathy.

SUBJECTS AND METHODS. One hundred forty-six consecutive patients with chronic renal insufficiency (serum creatinine > 1.5 mg/dL) were examined for renal artery stenosis using CO₂ and gadodiamide as the angiographic contrast agents. If renal artery stenosis was detected, percutaneous balloon angioplasty with or without stenting was performed. In patients for whom 48-hr creatinine levels were available, we performed an analysis to determine the incidence of contrast-involved nephropathy (increase in serum creatinine of 0.5 mg/dL at 48 hr without identifiable cause). Major complications were reported up to 1 week, and mortality was reported up to 30 days after the procedure.

RESULTS. Ninety-five patients had serum creatinine levels available at 48 hr. An increase in creatinine of greater than 0.5 mg/dL at 48 hr occurred in three patients (3.2%), presumably caused by CO₂, by gadodiamide, or by both. Neither diabetes nor the degree of preexisting chronic renal insufficiency was a predictor of worsening renal function 48 hr after the procedure. The volumes of CO₂ and gadodiamide used for diagnostic studies alone versus the volume used for interventional studies was not significantly different (for CO₂, p = 0.09; for gadodiamide, p = 0.30). Eleven major complications occurred in eight patients (5.5%). Two deaths (1.4%) occurred within 30 days. One death was due to cholesterol embolization and the other was not believed to be related to the procedure.

CONCLUSION. Angiography and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency and suspected ischemic nephropathy can be performed relatively safely using CO₂ and gadodiamide as angiographic contrast agents without an increased risk of complications. Contrast-induced nephropathy potentially occurred in 3.2% of patients. Neither the degree of underlying renal insufficiency nor diabetes was a risk factor for predicting a greater likelihood of renal function worsening at 48 hr of follow-up. The volumes of CO₂ and gadodiamide used in this study did not result in an increased risk of contrast-involved nephropathy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Perez-Rodriguez, S. Lai, B. D. Ehst, D. M. Fine, and D. A. Bluemke Nephrogenic Systemic Fibrosis: Incidence, Associations, and Effect of Risk Factor Assessment--Report of 33 Cases Radiology, February 1, 2009; 250(2): 371 - 377. [Abstract] [Full Text] [PDF]

				M. A. Perazella Current Status of Gadolinium Toxicity in Patients with Kidney Disease Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 461 - 469. [Abstract] [Full Text] [PDF]

				S. C. Josephs, H. A. Rowley, G. D. Rubin, and for Writing Group 3 Atherosclerotic Peripheral Vascular Disease Symposium II: Vascular Magnetic Resonance and Computed Tomographic Imaging Circulation, December 16, 2008; 118(25): 2837 - 2844. [Full Text] [PDF]

				G. C. Kane, A. W. Stanson, D. Kalnicka, D. W. Rosenthal, C. U. Lee, S. C. Textor, and V. D. Garovic Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1233 - 1240. [Abstract] [Full Text] [PDF]

				E. Balk, G. Raman, M. Chung, S. Ip, A. Tatsioni, A. Alonso, P. Chew, S. J. Gilbert, and J. Lau Effectiveness of Management Strategies for Renal Artery Stenosis: A Systematic Review Ann Intern Med, December 19, 2006; 145(12): 901 - 912. [Abstract] [Full Text] [PDF]

				P. C. Mannebach, R. S. Dieter, and D. S. Marks Use of Gadolinium-Based Angiography for Renal Artery Stenting in a Patient With Renal Insufficiency: A Case Report Angiology, August 1, 2006; 57(4): 526 - 529. [Abstract] [PDF]

				J. Ayerdi and K. J. Hodgson Balloon Angioplasty and Stenting for Renovascular Occlusive Disease Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2004; 16(1): 25 - 38. [Abstract] [PDF]